Drug research

Carboplatin

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Paraplatin

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNCT06246110	Eikon Therapeutics	Phase 2	Active not recruiting	2026-12Estimated
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaNCT05456256	LTRN	Phase 2	Recruiting	2026-12Estimated
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173	RCUS	Phase 2	Active not recruiting	2027-05Estimated
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381	Jazz Pharmaceuticals	Phase 2	Recruiting	2028-01-01Estimated
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerNCT06915025	Imunon	Phase 3	Recruiting	2032-10-31Estimated
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928	IOVA	Phase 2	Terminated	2026-02-20Actual

Eikon TherapeuticsActive not recruitingPrimary completion: 2026-12 · Estimated

Trial details

LTRNRecruitingPrimary completion: 2026-12 · Estimated

Trial details

RCUSActive not recruitingPrimary completion: 2027-05 · Estimated

Trial details

Jazz PharmaceuticalsRecruitingPrimary completion: 2028-01-01 · Estimated

Trial details

ImunonRecruitingPrimary completion: 2032-10-31 · Estimated

Trial details

IOVATerminatedPrimary completion: 2026-02-20 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.